In a whole-brain connectivity study, Yale researchers have developed a novel predictive model capable of predicting an individual’s behavior based on how their brain is wired.
Yale professor of chemistry David Spiegel and his company Kleo Pharmaceuticals are working to develop drug platforms that could be revolutionary immunotherapies for treating cancer and infectious diseases. “Kleo” is a synthesis of the names of Spiegel’s wife and son.